 JERUSALEM, July 8, 2019 PRNewswire -- BiondVax Pharmaceuticals Ltd. BVXV announced today that the first participants in the second cohort of the pivotal, clinical efficacy, Phase 3 trial of the M-001 universal flu vaccine candidate have been successfully enrolled. Influenza viruses mutate frequently and unpredictably, and the strains that dominate often vary in time and place. For example, according to the CDC, the first part of the 201819 flu season was dominated by H1 strains throughout most of the continental USA, while the south-east USA was dominated by an H3 strain. 